Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (2019 - 2025)

Keros Therapeutics' Shares Outstanding history spans 7 years, with the latest figure at $19.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 51.81% year-over-year to $19.5 million; the TTM value through Dec 2025 reached $19.5 million, down 51.81%, while the annual FY2025 figure was $19.5 million, 51.81% down from the prior year.
  • Shares Outstanding reached $40.7 million in Q4 2025 per KROS's latest filing, roughly flat from $40.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $40.7 million in Q4 2025 to a low of $23.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $31.6 million, with a median of $29.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 833.97% in 2021, then crashed 51.81% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $24.0 million in 2021, then increased by 14.88% to $27.5 million in 2022, then grew by 15.6% to $31.8 million in 2023, then increased by 27.37% to $40.6 million in 2024, then plummeted by 51.81% to $19.5 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Shares Outstanding are $19.5 million (Q4 2025), $40.6 million (Q3 2025), and $40.6 million (Q2 2025).